Patient-Centered Outcome Measures in Lung Cancer Trials

Lung

Volumn 194, Issue 4, 2016, Pages 647-652

  Schulkes, Karlijn J G ^a   Nguyen, Cindy ^a   van den Bos, Frederiek ^b   Hamaker, Marije E ^a   van Elden, Leontine J R ^a  

^a DEPARTMENT OF SURGERY   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

Author keywords

Lung cancer; Patient centered outcome measures; PROMs; Pulmonary malignancies

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; DISEASE COURSE; FUNCTIONAL STATUS; HEALTH CARE UTILIZATION; HUMAN; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SMALL CELL LUNG CANCER; VERY ELDERLY; WELLBEING; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; HEALTH SERVICE; HEALTH STATUS; LUNG TUMOR; MEDICAL RESEARCH; METHODOLOGY; MIDDLE AGED; MOTIVATION; PATIENT-REPORTED OUTCOME; REGISTER; STANDARDS; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; GOALS; HEALTH SERVICES; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; REGISTRIES; RESEARCH DESIGN; UNITED STATES; YOUNG ADULT;

EID: 84973595145     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-016-9903-2     Document Type: Article

References (32)

1. Laine C, Davidoff F (1996) Patient-centered medicine. A professional evolution. J Am Med Assoc: JAMA 275:152–156
2. Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742
3. Van den Berg JW, Venema G, Uil S, Kloosterziel C (2013) Chemo wordt te lang doorgezet. Med Contact 39:1974–1975
4. Hurria A, Mohile SG, Dale W (2012) Research priorities in geriatric oncology: addressing the needs of an aging population. J Natl Compr Cancer Netw 10:286–288
5. Bradley EH, Bogardus ST Jr, Tinetti ME, Inouye SK (1999) Goal-settings in clinical medicine. Soc Sci Med 49:267–278
6. Garrard L, Price LR, Bott MJ, Gajweski BR (2015) A novel method for expediting the development of patient-reported outcome measures and evaluation of its performance via simulation. BMC Med Res Methodol 15:77
7. Weenink J-W, Braspenning J, Wensing M (2014) Patient reported outcome measures (PROMs) in primary care: an observational pilot study of seven generic instruments. BMC Fam Pract 15:88
8. Anthoine E, Moret L, Regnault A, Sebille V, Hardouin J-B (2014) Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes 12:176
9. Acaster S, Cimms T, Lloyd A (2012) The design and selection of patient-reported utcomes measures (PROMs) for use in patient centered outcomes research. Patient Centered Outcomes Research Institute (PCORI)
10. www.cijfersoverkanker.nl
11. Matsuyama R, Reddy S, Smith T (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490–3496
12. Kastelijn EA, El Sharouni SY, Hofman FN, Van Putte BP, Monninkhof EM, Van Vulpen M, Schramel F (2015) Clinical outcomes in early-stage NSCLC treated with stereotactic body radiotherapy versus surgical resection. Anticancer Res 35:5607–5614
13. Agra Y, Pelayo M, Sacristan M, Sacristán A, Serra C, Bonfill X (2003) Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Databse Syst, Rev
14. Clinical Trials website April 25th 2016. https://clinicaltrials.gov/
15. Ma C, Bandukwala S, Burman D et al (2010) Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer 46:3175–3183
16. Baker A (2001) Crossing the quality chasm: a new health system for the 21st century. BMJ 323:1192. doi:10.1136/bmj.323.7322.1192
17. Department of Health (2008) High quality care for all. NHS next stage review. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/228836/7432.pdf
18. US Department of Health and Human Services Food, Drug Administration (2006) Guidance for industry: patient report outcome measures: use in clinical medical product development to support labelling claims: draft guidance. Health Qual Life Outcomes 4:79
19. Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson B (1992) Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 84:575–579
20. Speight J, Barendse SM (2010) FDA guidance on patient reported outcomes. Br Med J 340:2921
21. Quality of life and clinical trials (1995) Lancet 346:1–2
22. Corner J, Wright D, Hopkinson J et al (2007) The research priorities of patients attending UK cancer treatment centres: findings from a modified nominal group study. Br J Cancer 96:875–881
23. Goodare H, Smith R (1995) The rights of patients in research. Br Med J 310:1277–1278
24. Yellen GB, Cella DF, Leslie W (1994) Age and clinical decision making in oncology patients. J Natl Cancer Inst 86:1766–1770
25. Choulliara Z, Miller M, Stott D et al (2004) Older people with cancer: perceptions and feelings about information, decision-making and treatment—a pilot study. Eur J Oncol Nurs 8:257–261
26. Extermann M, Albrand G, Chen H et al (2003) Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol 21:3214–3219
27. Hurria A, Cohen HJ, Extermann M (2010) Geriatric oncology research in the cooperative groups: a report of a SIOG special meeting. J Geriatr Oncol 1:40–44
28. Meropol NJ, Egleston BL, Buzaglo JS et al (2008) Cancer patients preferences for quality and length of life. Cancer 113:3459–3466
29. Lichtman S (2012) Clinical trial design in older adults with cancer: the need for new paradigms. J Geriatr Oncol 3:368–375
30. Ardizzoni A, Favaretto A, Boni L et al (2005) Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis—a Forza Operativa Nazionale Italiana Carcinoma Polmonar. J Clin Oncol 23:569–575
31. Goldhirsch A, Gelber RD, Simes RJ et al (1989) Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7:36–44
32. Seymour MT, Thompson LC, Wasan HS et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label randomised factorial trial. Lancet 377:1749–1759